The global artificial insemination market size is to grow to USD 4121 million by 2030 at a CAGR of 9% from the early figures of USD 1929 million in 2021. Over the past few years, the number of people who cannot have children has been going up all over the world. According to a WHO survey from 2010, about 10% of women are affected by infertility in some way. The National Institutes of Health also said that about 12 percent of couples of reproductive age have trouble getting pregnant. Intrauterine Insemination (IUI) held most of the market share in 2018 and is likely to be one of the fastest-growing segments over the next few years. It is the most common way to start a family. Most of the time, it is a non-invasive procedure that can be done with or without drugs. When compared to other types of insemination, this method has a higher chance of success because the sperm sample is put closer to the eggs.
During the time frame of the forecast, intravaginal insemination is likely to be the second-fastest-growing segment. This process can be done at home or in a clinic for fertility. A number of medical centers that treat infertility have grown in large numbers over the past few years. This is because infertility has become more common around the world. In infertility clinics, invasive methods like intrauterine insemination and intratubal insemination are used to try to get a baby. Also, fertility clinics do something called "sperm washing," which cleans the sperm so it can be used for insemination. This helps increase the chances of getting pregnant.
Get more information on this report Download Sample Report
Around the world, the rate of infertility is going up because more people are getting diseases like erectile dysfunction and Polycystic Ovary Syndrome (PCOS). Changes in lifestyle and the fact that more working women want to have children later in life may cause problems. Men have trouble getting pregnant because of things like stress, drinking alcohol, a change in lifestyle, and a drop in the number and movement of sperm. The market for artificial insemination is driven by the constant rise of infertility in both men and women.
In order for artificial insemination to work, you need to know how far a sperm needs to travel to fertilize an egg. The type of insemination can be chosen based on why the woman cannot get pregnant. The most important factor in whether a woman gets pregnant naturally or with help is her age. After a woman turns 30, her ability to have children usually starts to go down. The number of people who cannot have children is highest in their late 30s and early 40s. Women over the age of 35 are said to have reached their "advanced reproductive age," and they should get checked out and treated early.
Over the past few years, the number of people who cannot have children has been going up around the world. WHO says that about 10% of women are affected by infertility, either directly or indirectly. In developing countries, one out of every four couples has trouble getting pregnant due to infertility. This affects about 12 percent of couples who are old enough to have children. Estimating information about infertility is still hard because both male and female infertility factors are complicated.
Even though IVF is considered a more advanced type of Assisted Reproductive Technology (ART), artificial insemination is usually the first step in treating infertility. ART was once forbidden because people thought it was immoral, unnatural, or unethical. People in the community, among family members, and among friends judged the families whose children were born through ARTs. The need for artificial insemination procedures is being driven by government programs and changes in the law.
About 14 states in the US have health insurance plans that cover treatment for infertility. In Canada, the government is taking steps to stop the population from going down. For example, it has paid for several cycles of IVF and artificial insemination. Also, Canadians who use fertility treatments can get tax credits of up to 40% from their government. In some cases, the NHS in the UK will pay for up to six Intrauterine Insemination (IUI) cycles.
Access to ARTs like artificial insemination is still hard to get in countries with few resources. WHO says that 180 million people around the world have problems getting pregnant. If you cannot get a diagnosis or treatment for infertility right away or it takes too long to get them, it could hurt your chances of getting pregnant. There is a big gap between the number of people who need reproductive health care in underdeveloped and developing countries and the number of people who can get it. Different countries have different rules about how to handle assisted reproduction. In some countries, like the US, scientific and medical committees at the national level have made rules for professionals.
Other countries have made laws about how ART can be used. The price is a big reason why people do not use artificial insemination. Some governments offer a small number of free IUI and IVF cycles, but the success rate is only average. Also, in some places, ART is not covered by health insurance for couples of the same gender. In some places, artificial insemination is seen as a socially unacceptable way to get pregnant. This means that children who were born through this method get a lot of criticism from their peers. Catechism says that artificial insemination is less wrong for married couples, but it is still morally wrong because it is an unnatural way to get pregnant.
Standardizing rules in different countries makes procedures more popular because it makes patients safer. Also, according to government rules, donors' names are kept secret. So, it gives couples who want to use artificial insemination a chance. Infertility solutions are not easy to find in underdeveloped countries, where about 10% of women have trouble getting pregnant and starting a family. Making people aware of the problems with infertility will help the market grow.
Due to more people learning about infertility treatments in developing countries and offering cost-effective, high-quality services to patients, the market has a lot of growth opportunities. Also, grants from the government to help set up clinics could give newcomers to the market more chances to make money. Several clinics are using the strategy of mergers and acquisitions to offer more services. This is a very common style choice in Spain, Australia, Sweden, and the UK. In May 2016, for example, Vitrolife bought Octax and MTG to add to their laser technology for treating infertility.
The global artificial insemination market share is segmented by type and by end-use.
The by-type segmentation of the said market is further categorized into Intrauterine Insemination and Intracervical Insemination, out of which the intrauterine insemination category owes the major market share.
Intrauterine insemination is the most dominant and popular type of artificial insemination market that accounts for a market value of USD 1433 million in 2021 and reaching to USD 3086 million by 2030 at a CAGR of 9%. Intrauterine Insemination (IUI) is a type of assisted reproductive technology that uses a catheter to put sperm directly into the uterus. IUI is the most common way of getting pregnant. Sperms are injected into the uterus to move them closer to the eggs and increase the chances of fertilization. IUI is planned around a woman's ovulation cycle to increase the chances of getting pregnant. Using ultrasound, hormonal analysis is used to track how the process is going.
Intracervical insemination is the second leading by-type segmentation with a market value of USD 2120 million in 2021 and is expected to grow to USD 439 million by 2030 at a CAGR of 8%. Intracervical Insemination (ICI) involves injecting sperm into the outer part of a woman's cervix so that the sperm can move on its own into the uterus and fallopian tubes. This method of insemination is less common than IUI and IVI because it does not lead to as many pregnancies.
By end-use segmentation, the said market is further categorized into fertility clinics and homes, where fertility clinics dominate the market share.
The fertility clinics owe the major market share in the said segmentation with a market value of USD 1694 million in 2021 and growing to USD 3530 million by 2030 at a CAGR of 9%. At fertility clinics, all kinds of artificial insemination procedures can be done. In infertility clinics, most Intrauterine Insemination (IUI) and Intratubal Insemination (ITI) procedures are done. Before starting the insemination process at a clinic, a consultation is needed to find out when the woman is likely to ovulate. Also, doctors can give you medicine to increase your chances of getting pregnant.
Home end-user accounts for a market value of USD 235 million in 2021 and is expected to reach USD 454 million in 2030 at a CAGR of 8%. You can do both Intracervical Insemination (ICI) and Intravaginal Insemination (IVI) at home. With home insemination kits, a sample of sperm can be put in the cervix or vaginal area. To get the best results, these techniques should be done around the time of ovulation.
The global artificial insemination market is primarily divided into three regions, namely North America, Europe, and Asia-Pacific. Europe is the most dominant region having a major share of the market.
Regional Growth Insights Request Sample Pages
Europe accounts for a market value of USD 749 million in 2021 and is expected to reach USD 1600 million by 2030 at a CAGR of 9%. Europe is said to be one of the top healthcare facility providers in the world, which is why it is also leading the said market segment with the availability of resources and ample awareness among the people.
Asia-Pacific is the second dominant region in the said market segment, with a market value of USD 593 million in 2021 and growing at a CAGR of 9% to USD 1287 million. Asia-Pacific is soon to be developed as the hub healthcare facilities owing to the developments in the said industry happening in the region, which is why the said market is having a stable growth in Asia-Pacific.
North America has listed as the third region in the said segmentation, has a market value of USD 451 million in 2021, and is anticipated to grow to USD 917 million by 2030 at a CAGR of 8%.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Type (Intrauterine Insemination, Intracervical Insemination), End-Use (Fertility Clinics, Home)|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Vitrolife, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Fujifilm Irvine Scientific, Kitazato Corporation,|
|Key Market Opportunities||Increasing Prevalence Of The Medical Devices Industry Enhances The Expansion Of The Artificial Insemination Market Share|